Spatiotemporally controlled systemic delivery reshapes the in vivo fate of a cationic antimicrobial peptide for lung-selective exposure and an improved therapeutic index

  • Eur J Pharm Biopharm. 2026 Jul:224:115081. doi: 10.1016/j.ejpb.2026.115081.
Weiyan Tao  1 ,  Mingzhen Li  2 ,  Yunlin Zhou  3 ,  Kexin Liu  4 ,  Guoqiu Wu  5 ,  Jingru Guo  6 ,  Bin Di  7
Affiliations
  • 1. Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China. Electronic address: [email protected].
  • 2. Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China. Electronic address: [email protected].
  • 3. Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China. Electronic address: [email protected].
  • 4. Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China. Electronic address: [email protected].
  • 5. Center of Clinical Laboratory Medicine, Zhongda Hospital, Southeast University, Nanjing 210009, China; Department of Laboratory Medicine, Medical School of Southeast University, Nanjing 210009, China. Electronic address: [email protected].
  • 6. Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China. Electronic address: [email protected].
  • 7. Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China. Electronic address: [email protected].
PMID: 42044857 DOI: 10.1016/j.ejpb.2026.115081
Abstract

A key biopharmaceutic barrier in systemic treatment of pulmonary infections is achieving sufficient drug exposure at infected lung sites with cationic antimicrobial peptides (AMPs), which are prone to proteolytic degradation, rapid clearance, and off-target interactions in circulation. S-thanatin (Ts) is a cationic AMP with potent in vitro Antibacterial activity and low resistance liability, yet its unfavorable in vivo fate limits therapeutic efficacy. To address this limitation, we implemented a spatiotemporally controlled systemic delivery strategy that couples pathogen-associated localization with enzyme-activated, on-site release. As a practical formulation to realize this concept, Ts@CPN@PM was electrostatically assembled with bacteria-pre-stimulated macrophage membranes for pathogen-associated targeting and equipped with a matrix metalloproteinase-3 (MMP-3)-cleavable NFF-3 switch for infection-microenvironment-triggered release. Ts@CPN@PM achieved ∼95 % in vitro Ts release under elevated MMP-3 conditions and preferentially accumulated in infected lungs (>70 % by fluorescence quantification). In an antibiotic-resistant E. coli pneumonia model, Ts@CPN@PM improved survival (10 % to 60 %), reduced pulmonary Bacterial burden (∼2 log CFU/g), and attenuated inflammatory responses. Ts@CPN@PM showed favorable cytocompatibility and hemocompatibility in vitro, and systemic biosafety was confirmed in healthy mice. Overall, these findings support spatiotemporal control of lung-site exposure as a feasible route to improve the in vivo fate and therapeutic index of cationic AMPs for pulmonary Bacterial infections.

Keywords
Cationic antimicrobial peptide; Infection microenvironment-responsive release; Lung-site exposure; Pathogen-associated targeting; Spatiotemporally control; Systemic delivery.
Products